Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers
Open Access
- 4 April 2013
- journal article
- Published by Spandidos Publications in Oncology Reports
- Vol. 29 (6) , 2415-2421
Abstract
Neuroblastoma is a tumor accounting for approximately 10% of all childhood malignancies and 50% of all childhood cancer-related deaths. MYCN gene copy number variation represents the most important prognostic factor in neuroblastoma. Prognostic significance of MYCN gene expression is more complicated and may depend on other factors such as MYCN gene copy number status. In the present study, we assessed MYCN gene expression using real-time RT-PCR following cisplatin treatment in three human neuroblastoma cell lines (UKF-NB-3, UKF-NB-4 and SK-N-AS) and their cisplatin-resistant counterparts. We also examined MYCN gene status and copy number (gain and amplification) variations using interphase and metaphase fluorescent in situ hybridization (FISH) and multiplex ligation-dependent probe amplification (MLPA). Only cisplatin-sensitive UKF-NB-4 cells exhibited decreased MYCN expression following treatment with cisplatin. Other sensitive neuroblastoma cells did not exhibit a change in MYCN expression. In contrast, cisplatin-resistant UKF-NB-4 and SK-N-AS cells exhibited increased MYCN expression irrespective of the number of MYCN copies or concentration of cisplatin in the medium. In MYCN-amplified neuroblastoma cells we did not observe any significant change in the number of MYCN copies after cisplatin treatment, whereas MYCN-non-amplified SK-N-AS cells revealed during cisplatin treatment an increased number of MYCN gene copies caused by 2p gain in the majority of cells by FISH. We postulated that cisplatin treatment does not result directly in altered transcription of MYCN. A functional change in MYCN mRNA levels and increased MYCN expression in cisplatin-resistant neuroblastoma cells do not have a clear relationship to MYCN copy numbers. These findings may further contribute to the understanding of cisplatin chemotherapy in connection with MYCN expression, and the possible copy number variations in MYCN neuroblastoma cells may be of importance since targeting of MYCN is being tested as neuroblastoma therapy.Keywords
This publication has 36 references indexed in Scilit:
- The MYCN oncogene and differentiation in neuroblastomaSeminars in Cancer Biology, 2011
- Identification of therapy-sensitive and therapy-resistant neuroblastoma subtypes in stages III, IVs and IVCancer Letters, 2011
- The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastomaPediatric Surgery International, 2010
- Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristineCancer Genetics and Cytogenetics, 2010
- International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology CommitteeBritish Journal of Cancer, 2009
- NeuroblastomaThe Lancet, 2007
- The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell lineCarcinogenesis, 2004
- MYCN in neuronal tumoursCancer Letters, 2004
- Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas StimulationJournal of Biological Chemistry, 2004
- Proliferation, cell cycle and apoptosis in cancerNature, 2001